JP2020522520A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522520A5 JP2020522520A5 JP2019566754A JP2019566754A JP2020522520A5 JP 2020522520 A5 JP2020522520 A5 JP 2020522520A5 JP 2019566754 A JP2019566754 A JP 2019566754A JP 2019566754 A JP2019566754 A JP 2019566754A JP 2020522520 A5 JP2020522520 A5 JP 2020522520A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- amino
- aminocyclohexyl
- solvate
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(NC1CCCCCCCCCCCC1)=NC=C(C(C)=C(C(*)=C1*)C2=CC=CC(N)=CC(NS(C3=C(*)C=C*(*)C=C3)(=O)=O)=CC=CC=C2)C1=* Chemical compound CC(NC1CCCCCCCCCCCC1)=NC=C(C(C)=C(C(*)=C1*)C2=CC=CC(N)=CC(NS(C3=C(*)C=C*(*)C=C3)(=O)=O)=CC=CC=C2)C1=* 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513929P | 2017-06-01 | 2017-06-01 | |
| US62/513,929 | 2017-06-01 | ||
| PCT/US2018/035465 WO2018222918A1 (en) | 2017-06-01 | 2018-05-31 | Ire1 small molecule inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020522520A JP2020522520A (ja) | 2020-07-30 |
| JP2020522520A5 true JP2020522520A5 (enExample) | 2021-02-12 |
| JP7126084B2 JP7126084B2 (ja) | 2022-08-26 |
Family
ID=64455585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566754A Expired - Fee Related JP7126084B2 (ja) | 2017-06-01 | 2018-05-31 | Ｉｒｅ１小分子阻害薬 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20180346446A1 (enExample) |
| EP (1) | EP3630748B1 (enExample) |
| JP (1) | JP7126084B2 (enExample) |
| AU (1) | AU2018278311B2 (enExample) |
| CA (1) | CA3064837A1 (enExample) |
| WO (1) | WO2018222918A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018102751A1 (en) | 2016-12-02 | 2018-06-07 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
| AU2018278311B2 (en) | 2017-06-01 | 2021-10-07 | Cornell University | IRE1 small molecule inhibitors |
| WO2019094641A1 (en) * | 2017-11-10 | 2019-05-16 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
| TWI831829B (zh) | 2018-09-12 | 2024-02-11 | 美商建南德克公司 | 苯氧基-吡啶基-嘧啶化合物及使用方法 |
| JP7546299B2 (ja) | 2018-12-03 | 2024-09-06 | コーネル・ユニバーシティー | Ｉｒｅ１小分子阻害物質 |
| WO2020142612A1 (en) | 2019-01-03 | 2020-07-09 | Genentech, Inc. | Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases. |
| TWI756636B (zh) * | 2019-02-18 | 2022-03-01 | 美商建南德克公司 | 嘧啶并嘧啶化合物及使用方法 |
| SG11202109194UA (en) * | 2019-02-27 | 2021-09-29 | Optikira Llc | Pyrazolopyridine compounds for ire1 inhibition |
| US20220194945A1 (en) * | 2019-02-27 | 2022-06-23 | Optikira, LLC | Imidazolopyridine Compounds For IRE1 Inhibition |
| US20220265656A1 (en) * | 2019-05-15 | 2022-08-25 | Cornell University | Combination therapies with ire1 small molecule inhibitors |
| US12479818B2 (en) | 2019-05-15 | 2025-11-25 | Cornell University | Treatment of fibrosis with IRE1 small molecule inhibitors |
| EP3983400B1 (en) * | 2019-06-11 | 2025-05-28 | Genentech, Inc. | Quinazolinyl compounds and methods of use |
| KR20220097438A (ko) * | 2019-11-01 | 2022-07-07 | 얀센 바이오테크 인코포레이티드 | 암, 자가면역, 및 염증성 질환의 치료를 위한 다이하이드로오로테이트 데하이드로게나제(dhodh) 억제제로서의 플루오르화 퀴놀린 및 퀴녹살린 유도체 |
| US20240262830A1 (en) * | 2020-02-03 | 2024-08-08 | Nimbus Iaso, Inc. | Ire1a modulators and uses thereof |
| EP4107146A1 (en) * | 2020-02-17 | 2022-12-28 | Alesta Therapeutics BV | Gcn2 modulator compounds |
| CA3188602A1 (en) * | 2020-08-07 | 2022-02-10 | Richard Keenan | Pyrazolopyridine compounds and methods of inhibiting ire1 using same |
| CN116710429A (zh) * | 2020-11-13 | 2023-09-05 | 加利福尼亚大学董事会 | IRE1α抑制剂及其用途 |
| PE20231311A1 (es) | 2020-11-18 | 2023-08-24 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos |
| MX2024006627A (es) | 2021-12-03 | 2024-08-22 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos. |
| WO2024131893A1 (en) * | 2022-12-22 | 2024-06-27 | Shanghai Yi Zhong Xing Biotechnology Co., Ltd. | IRE1α SMALL MOLECULE INHIBITORS |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1626056B1 (en) | 1999-12-30 | 2012-03-28 | President and Fellows of Harvard College | Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| EP1878727A4 (en) | 2005-04-28 | 2013-11-13 | Kyowa Hakko Kirin Co Ltd | 2-AMINOQUINAZOLINE DERIVATIVES |
| US8017331B2 (en) * | 2005-11-04 | 2011-09-13 | Mannkind Corporation | IRE-1α substrates |
| WO2007101225A2 (en) | 2006-02-27 | 2007-09-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods to identify inhibitors of the unfolded protein response |
| US8227184B2 (en) | 2008-01-14 | 2012-07-24 | President And Fellows Of Harvard College | Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity |
| US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| MX2012011504A (es) * | 2010-04-05 | 2013-01-18 | Mannkind Corp | Inhibidores de enzima 1 dependiente de inositol (ire-1 alfa). |
| US9956236B2 (en) | 2011-02-07 | 2018-05-01 | Cornell University | Methods for increasing immune responses using agents that directly bind to and activate IRE-1 |
| US9422298B2 (en) * | 2011-03-17 | 2016-08-23 | Cmg Pharmaceutical Co., Ltd. | Pyridopyrimidine derivatives and use thereof |
| US20150018406A1 (en) | 2012-03-09 | 2015-01-15 | Cornell University | Modulation of breast cancer growth by modulation of xbp1 activity |
| CA2886240A1 (en) * | 2012-09-26 | 2014-04-03 | The Regents Of The University Of California | Modulation of ire1 |
| WO2014176348A1 (en) | 2013-04-23 | 2014-10-30 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibitors of the ire-1/xbp-1 pathway and methods of using thereof |
| EP3049521B1 (en) | 2013-09-25 | 2019-03-06 | Cornell University | Compounds for inducing anti-tumor immunity and methods thereof |
| US9682123B2 (en) * | 2013-12-20 | 2017-06-20 | The Trustees Of Columbia University In The City Of New York | Methods of treating metabolic disease |
| AU2017228398A1 (en) | 2016-03-03 | 2018-10-18 | Cornell University | Small molecule IRE1-alpha inhibitors |
| WO2018102751A1 (en) | 2016-12-02 | 2018-06-07 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
| WO2018161033A1 (en) | 2017-03-02 | 2018-09-07 | Wright, Adrian | Small molecule ire1-alpha inhibitors |
| TW201838981A (zh) | 2017-03-17 | 2018-11-01 | 美商建南德克公司 | 嘧啶基-吡啶氧基-萘基化合物以及治療ire1相關之疾病及病症的方法 |
| AU2018278311B2 (en) | 2017-06-01 | 2021-10-07 | Cornell University | IRE1 small molecule inhibitors |
| WO2019094641A1 (en) * | 2017-11-10 | 2019-05-16 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
-
2018
- 2018-05-31 AU AU2018278311A patent/AU2018278311B2/en not_active Ceased
- 2018-05-31 US US15/994,901 patent/US20180346446A1/en not_active Abandoned
- 2018-05-31 CA CA3064837A patent/CA3064837A1/en active Pending
- 2018-05-31 WO PCT/US2018/035465 patent/WO2018222918A1/en not_active Ceased
- 2018-05-31 EP EP18809060.9A patent/EP3630748B1/en active Active
- 2018-05-31 JP JP2019566754A patent/JP7126084B2/ja not_active Expired - Fee Related
-
2019
- 2019-08-16 US US16/543,188 patent/US11021466B2/en active Active
-
2021
- 2021-05-06 US US17/313,688 patent/US11649224B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016534134A5 (enExample) | ||
| CA2822039C (en) | Sulfur derivatives as chemokine receptor modulators | |
| JP2016509591A5 (enExample) | ||
| JP2022511477A5 (enExample) | ||
| JP2019507179A5 (enExample) | ||
| JP2022506887A5 (enExample) | ||
| JP2021502387A5 (enExample) | ||
| JP2009524691A5 (enExample) | ||
| JP2007504160A5 (enExample) | ||
| JP2016500107A5 (ja) | グルタミナーゼ阻害剤およびその使用方法 | |
| JP2007530459A5 (enExample) | ||
| SI2824100T1 (en) | 1,2,5-oxadiazoles as inhibitors of indolamine 2,3-dioxygenase | |
| JP2010510237A5 (enExample) | ||
| JP2004517087A5 (enExample) | ||
| JP2015517981A5 (enExample) | ||
| JP2022549222A5 (enExample) | ||
| JP2020504707A5 (enExample) | ||
| JPWO2007126043A1 (ja) | チアゾール環を含むカルボン酸誘導体の医薬用途 | |
| RU2017145930A (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORγ) | |
| HRP20100283T1 (hr) | Derivati n-'(1,5-difenil-1h-pirazol-3-il)sulfonamida s afinitetom za cb1 receptor | |
| JP2019510025A5 (enExample) | ||
| JP2019532092A5 (enExample) | ||
| JP2016527184A5 (enExample) | ||
| JP2012528839A5 (enExample) | ||
| JP2010522770A5 (enExample) |